AVENGE BIO

Principal Scientist, Preclinical Development

Responsibilities:

- Responsible for managing a broad range of preclinical activities in support of preIND and IND filing activities
- Plan, design, and execute preclinical efficacy studies and safety studies
- Proven ability to focus on multiple priorities to drive programs forward simultaneously
- Identify, plan, coordinate and supervise study execution at external CROs
- Author technical reports and regulatory filings for preINDs and INDs
- Applies advanced technical writing skills to produce reports, presentations and documents
- Communication of experimental plans and data to multiple cross-functional scientific teams

Qualifications:

- PhD degree in biology, biochemical engineering, or relevant field with at least 5+ years of relevant industry experience
- Strong technical understanding and experience in biopharmaceutical product lifecycle management
- Proven experience with preparation of regulatory documents for preIND and IND filings
- Previous experience with cell and/or gene therapy is required
- Knowledge of regulatory guidelines for IND and BLA filing is a plus
- Good writing and communication skills; ability to understand and communicate scientific information
- Highly collaborative working style, and ability to adapt in a fast-paced environment
- Ability to work with minimal direction to meet objectives and timelines, adapting to changes and priorities in order to fulfill our mission

The role reports to the Senior Director of Product Development.

About Avenge Bio

Avenge Bio, Inc. is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyte™ platform. Avenge Bio recently announced a Series A financing and plan to use this funding to progress the lead program, AVB-001, into the clinic for the treatment of ovarian cancer. Investors include Longitude Capital, CAM Capital, Perceptive Xontogeny Venture Fund, Rock Springs Capital and Pappas Capital. The LOCOcyte™ platform leverages proprietary engineered cells delivered to the local tumor environment that generate high concentrations of immune effector molecules in proximity to the tumor. This initiates a robust, local and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and

is initially being studied in metastatic peritoneal cancers such as ovarian cancer. Avenge has additional pipeline candidates for the treatment of a wide range of cancers including pancreatic, lung and breast cancers. Avenge Bio was founded in 2019 based upon technology developed in the laboratory of Omid Veiseh, Ph.D. and has an exclusive license from Rice University for this technology. To learn more, visit www.avengebio.com.